[go: up one dir, main page]

BR0312393A - Tratamento de infertilidade com exemestano - Google Patents

Tratamento de infertilidade com exemestano

Info

Publication number
BR0312393A
BR0312393A BR0312393-6A BR0312393A BR0312393A BR 0312393 A BR0312393 A BR 0312393A BR 0312393 A BR0312393 A BR 0312393A BR 0312393 A BR0312393 A BR 0312393A
Authority
BR
Brazil
Prior art keywords
exemestane
infertility treatment
infertility
treatment
administering
Prior art date
Application number
BR0312393-6A
Other languages
English (en)
Inventor
Charles P Wajszczuk
Hendrik J Dekoning Gans
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of BR0312393A publication Critical patent/BR0312393A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"TRATAMENTO DE INFERTILIDADE COM EXEMESTANO". A presente invenção refere-se a um método de terapia para tratamento de infertilidade em um hospedeiro feminino, compreendendo a adminsitração de uma quantidade eficaz de estimulação folicular ovariana de exemestano.
BR0312393-6A 2002-07-02 2003-07-02 Tratamento de infertilidade com exemestano BR0312393A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39332002P 2002-07-02 2002-07-02
PCT/US2003/016252 WO2004004634A2 (en) 2002-07-02 2003-07-02 Infertility treatment with exemestane

Publications (1)

Publication Number Publication Date
BR0312393A true BR0312393A (pt) 2005-04-12

Family

ID=30115565

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312393-6A BR0312393A (pt) 2002-07-02 2003-07-02 Tratamento de infertilidade com exemestano

Country Status (12)

Country Link
EP (1) EP1531829A2 (pt)
JP (1) JP2005536490A (pt)
KR (1) KR20050077045A (pt)
CN (1) CN1665516A (pt)
AU (1) AU2003247404A1 (pt)
BR (1) BR0312393A (pt)
CA (1) CA2491372A1 (pt)
IL (1) IL165813A0 (pt)
MX (1) MXPA05000251A (pt)
PL (1) PL373219A1 (pt)
WO (1) WO2004004634A2 (pt)
ZA (1) ZA200410135B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102432156B1 (ko) * 2020-05-18 2022-08-11 제주대학교 산학협력단 화학물질을 포함하는 어류의 성 성숙 제어용 조성물 및 이를 이용한 어류의 성 성숙 제어방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ299735B6 (cs) * 2001-04-17 2008-11-05 Ares Trading S. A. Farmaceutický prostredek
PL366744A1 (en) * 2001-04-17 2005-02-07 Ares Trading S.A. Single dose aromatase inhibitor for treating infertility

Also Published As

Publication number Publication date
PL373219A1 (en) 2005-08-22
ZA200410135B (en) 2006-07-26
MXPA05000251A (es) 2005-07-15
IL165813A0 (en) 2006-01-15
WO2004004634A2 (en) 2004-01-15
AU2003247404A1 (en) 2004-01-23
KR20050077045A (ko) 2005-07-29
CA2491372A1 (en) 2004-01-15
EP1531829A2 (en) 2005-05-25
CN1665516A (zh) 2005-09-07
WO2004004634A3 (en) 2004-04-08
JP2005536490A (ja) 2005-12-02

Similar Documents

Publication Publication Date Title
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BRPI0410927A (pt) métodos terapêuticos e profiláticos para distúrbios neuromusculares
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
BRPI0418029A (pt) formulação de anticorpos cd40 e métodos
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
MX344587B (es) Metodo para incrementar la estabilidad in vitro e in vivo de enzimas asociadas al transtorno lisosomal.
BR0315597A (pt) Processos de baixa dose para tratamento de distúrbios em que a atividade de tnf(alfa)é prejudicial
MY151032A (en) Treatment of tnf? related disorders
AU2003219107A8 (en) Tuberculosis treatment using pleuromutilin derivatives
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BR0211830A (pt) Dose única de azitromicina
PT1030667E (pt) Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
BRPI0716929A8 (pt) tratamento de esclerose múltipla com campath-1h
BR0312393A (pt) Tratamento de infertilidade com exemestano
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
MXPA01007031A (es) Metodo para tratar enfermedades acrdiacas cronicas.
BR0308753A (pt) Método para produzir pseudo-ilhotas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.